Revenue: As of FY2025 Q3, the actual value is USD 1 K.EPS: As of FY2025 Q3, the actual value is USD -0.11, meeting the estimate of USD -0.11.EBIT: As of FY2025 Q3, the actual value is USD -3.503 M.<h3>Financial Metrics by Segment</h3><h4>Segment Revenue</h4><ul><li>Revenue for the three months ended September 30, 2025: $1,000</li><li>Revenue for the nine months ended September 30, 2025: $28,000</li></ul><h4>Operational Metrics</h4><ul><li>Net Loss:<ul><li>Three months ended September 30, 2025: - $4,436,000</li><li>Nine months ended September 30, 2025: - $10,518,000</li></ul></li><li>Research and Development Expenses:<ul><li>Three months ended September 30, 2025: $1,803,000</li><li>Nine months ended September 30, 2025: $4,472,000</li></ul></li><li>Selling, General and Administrative Expenses:<ul><li>Three months ended September 30, 2025: $1,620,000</li><li>Nine months ended September 30, 2025: $5,587,000</li></ul></li><li>Total Operating Costs and Expenses:<ul><li>Three months ended September 30, 2025: $3,423,000</li><li>Nine months ended September 30, 2025: $10,059,000</li></ul></li><li>Loss from Operations:<ul><li>Three months ended September 30, 2025: - $3,422,000</li><li>Nine months ended September 30, 2025: - $10,031,000</li></ul></li><li>Other (Expense) Income, Net:<ul><li>Three months ended September 30, 2025: - $1,014,000</li><li>Nine months ended September 30, 2025: - $560,000</li></ul></li></ul><h4>Cash Flow</h4><ul><li>Net Cash Used in Operating Activities:<ul><li>Nine months ended September 30, 2025: - $8,928,000</li></ul></li><li>Net Cash (Used in) Provided by Investing Activities:<ul><li>Nine months ended September 30, 2025: - $17,815,000</li></ul></li><li>Net Cash Provided by Financing Activities:<ul><li>Nine months ended September 30, 2025: $21,337,000</li></ul></li></ul><h4>Unique Metrics</h4><ul><li>Warrant Liability:<ul><li>September 30, 2025: $1,854,000</li><li>December 31, 2024: $1,061,000</li></ul></li><li>Liability Related to the Sale of Future Payments:<ul><li>September 30, 2025: $6,499,000</li><li>December 31, 2024: $6,527,000</li></ul></li></ul><h4>Future Outlook and Strategy</h4><ul><li>Core Business Focus:<ul><li>Talphera, Inc. is focused on developing and commercializing innovative therapies for use in medically supervised settings, with a primary focus on Niyad, a regional anticoagulant for the dialysis circuit, and LTX-608, a nafamostat formulation for direct IV infusion for various indications.</li><li>The company plans to expand its portfolio to include additional acute care therapies for use in medically supervised settings.</li></ul></li><li>Non-Core Business:<ul><li>The company may seek to raise additional capital through public or private equity offerings, debt securities, a new debt facility, or entering into product development, license, or distribution agreements with third parties.</li><li>Talphera, Inc. is also considering divesting any of its remaining product candidates to fund its planned operations.</li></ul></li></ul>

Talphera | 10-Q: FY2025 Q3 Revenue: USD 1 K